Articles From: Employment Outlook for Service Members Continues to Improve, But Translating Skills to Civilian Jobs Still a Challenge for Many Veterans, Reveals University of Phoenix Survey to Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference


2014/11/10
A new University of Phoenix national military survey suggests that while the veteran unemployment rate continues to decline i , many veterans may actually be underemployed.
Sign-up for Employment Outlook for Service Members Continues to Improve, But Translating Skills to Civilian Jobs Still a Challenge for Many Veterans, Reveals University of Phoenix Survey investment picks
2014/10/24
MEXICO CITY, Oct.
Sign-up for Empresas ICA Announces Unaudited Third Quarter 2014 Results investment picks
Emulex Corporation (NYSE:ELX) and Dynatrace today announced NetPod™, a fully integrated solution that combines Dynatrace’s Data Center (DC RUM) analysis with Emulex’s EndaceProbe™ Intelligent Network Recorders.
Sign-up for Emulex and Dynatrace Deliver NetPod for Application-Aware Network Performance Management with High-Speed Network Data Capture and Storage investment picks
OPENSTACK SUMMIT – Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced a family of Emulex ExpressConfig™ Solutions designed to help IT professionals optimize I/O connectivity for cloud, hyperscale and enterprise environments.
Sign-up for Emulex Announces Family of ExpressConfig Solutions to Optimize Cloud, Hyperscale and Enterprise Environments investment picks
Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced earnings results for the first quarter of fiscal 2015 ending September 28, 2014.
Sign-up for Emulex Announces Fiscal 2015 First Quarter Results investment picks
COSTA MESA, Calif.
Sign-up for Emulex Announces Preliminary Second Quarter Financial Results investment picks
Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced that it has joined the 25Gb Ethernet (25GbE) Consortium to drive industry standardization.
Sign-up for Emulex Joins 25Gb Ethernet Consortium to Drive Industry Standardization investment picks
Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced new Emulex Virtual Fabric Adapter 5 (VFA5) technology for the new Lenovo servers, based on the new Intel Xeon processor E5-2600/1600 v3 product families.
Sign-up for Emulex Provides 10Gb Ethernet Virtual Fabric Adapter 5 for New Lenovo Servers investment picks
POWERING THE CLOUD – Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, announced the results of a study of 1,623 U.S. and European IT professionals, in which respondents provided insight into their enterprise data center networking environments.
Sign-up for Emulex Study Reveals Bandwidth and Network Speeds Exploding with Hyperscale Deployments investment picks
2014/11/3
Emulex Corporation: WHAT: About Emulex Emulex, a leader in network connectivity, monitoring and management, provides hardware and software solutions for global networks that support enterprise, cloud, government and telecommunications.
Sign-up for Emulex to Present at 2014 RBC Capital Markets’ Technology, Internet, Media & Telecommunications Conference investment picks
Emulex Corporation: WHAT: Emulex Corporation (NYSE:ELX) will present to investors attending the Needham Growth Conference on Tuesday, January 13, 2015 at 6:20 a.m. Pacific time.
Sign-up for Emulex to Present at 2015 Needham Growth Conference investment picks
Emulex Corporation (NYSE:ELX): WHAT: About Emulex Emulex, a leader in network connectivity, monitoring and management, provides hardware and software solutions for global networks that support enterprise, cloud, government and telecommunications.
Sign-up for Emulex to Present at Barclays 2014 Global Technology Conference investment picks
2014/11/20
Emulex Corporation: WHAT: About Emulex Emulex, a leader in network connectivity, monitoring and management, provides hardware and software solutions for global networks that support enterprise, cloud, government and telecommunications.
Sign-up for Emulex to Present at Credit Suisse 2014 Annual Technology Conference investment picks
Enable Midstream Partners, LP (NYSE: ENBL) will announce full-year and fourth-quarter 2014 financial results before market hours Wednesday, Feb.
Sign-up for Enable Midstream Announces Year-End and Fourth-Quarter 2014 Financial Results Release Date and Conference Call Information investment picks
Enable Midstream Partners, LP (NYSE:ENBL) today announced that the board of directors of its general partner has declared a quarterly cash distribution of $0.3025 per unit on all outstanding common and subordinated units for the quarter ended Sept.
Sign-up for Enable Midstream Partners Increases Quarterly Distribution investment picks
The Board of Directors of Enable Midstream Partners, LP (NYSE: ENBL) today announced that Paul A.
Sign-up for Enable Midstream Partners Names Paul A. Weissgarber Chief Commercial Officer investment picks
Enable Midstream Partners, LP (NYSE:ENBL) today announced that effective Feb.
Sign-up for Enable Midstream Partners to Add Independent Director in 2015 investment picks
DALLAS , Nov.
Sign-up for Enable Midstream Partners To Join The Alerian Natural Gas MLP Index investment picks
Enable Midstream Partners, LP (NYSE: ENBL) (the "Partnership”) today announced financial results for third quarter 2014.
Sign-up for Enable Midstream Reports Third Quarter 2014 Financial Results investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie’s investigational, all-oral, interferon-free treatment of VIEKIRAX™ (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA™ (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX™ only, with RBV, for patients with genotype 4 (GT4) HCV infection.
Sign-up for Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
Enanta Announces European Commission Grants Marketing Authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Genotypes 1 and 4 Chronic Hepatitis C Virus Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European Commission has granted marketing authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) 1,2 with or without ribavirin (RBV) for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Sign-up for Enanta Announces European Commission Grants Marketing Authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets)... investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced detailed results from AbbVie’s open-label, Phase 2b PEARL-I study in patients with genotype 4 (GT4) chronic hepatitis C virus (HCV). PEARL-I studied AbbVie’s all-oral, interferon-free investigational treatment combining two direct-acting antivirals (ABT-450/ritonavir and ombitasvir) with or without ribavirin (RBV) for 12 weeks in non-cirrhotic adult patients with chronic genotype 1b (GT1b) and GT4 hepatitis C virus (HCV) infection.
Sign-up for Enanta Announces Results from Phase 2b PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting 2014® investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced at The Liver Meeting ® 2014 results from studies in chronic hepatitis C virus (HCV) patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I). New, detailed results from part one of the Phase 2 portion of AbbVie’s Phase 2/3 open-label study, TURQUOISE-I, showed that patients co-infected with genotype 1 (GT1) HCV and HIV-1 receiving AbbVie’s investigational treatment and ribavirin (RBV) for 12 weeks or 24 weeks achieved a sustained virologic response rate 12 weeks post-treatment (SVR 12 ) of 93.5 percent (n=29/31) and 90.6 percent (n=29/32), respectively.
Sign-up for Enanta Announces Results from TURQUOISE-I Study in Chronic Hepatitis C Patients with HIV-1 Co-infection and from the CORAL-I Study In Liver Transplant Recipients at The Liver Meeting 2014® investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced the U.S. Food and Drug Administration (FDA) has approved AbbVie’s VIEKIRA PAK™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) with or without ribavirin for the treatment of genotype 1 (GT1) patients with chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis.
Sign-up for Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). NASDAQ has announced that the annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
Sign-up for Enanta Pharmaceuticals Added to the NASDAQ Biotechnology Index investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal fourth quarter and year ended September 30, 2014.
Sign-up for Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2014 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it plans to report its fiscal fourth quarter and year ended September 30, 2014 financial results before the U.S. markets open on November 24, 2014.
Sign-up for Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2014 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Employment Outlook for Service Members Continues to Improve, But Translating Skills to Civilian Jobs Still a Challenge for Many Veterans, Reveals University of Phoenix Survey to Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent